IBB - (iShares Nasdaq Biotechnology Index Fund)

 IBBのチャート


 IBBの企業情報

symbol -
会社名
分野(sector)   
産業(industry)   
業種   
概要     
本社所在地 --
代表者氏名
代表者役職名
電話番号 --
設立年月日 --
市場名 --
ipoyear ―年
従業員数 --
url --
nasdaq_url https://www.nasdaq.com/symbol/ibb
adr_tso
EBITDA
終値(lastsale) 115.69
時価総額(marketcap) 9145294500
時価総額
売上高
企業価値(EV)
当期純利益
決算概要

 IBBのテクニカル分析


 IBBのニュース

   5 Biotech Stocks That Generated 1,000%+ Returns In 2020  2020/12/26 15:30:02 Benzinga
The biopharma sector weathered the COVID-19 pandemic fairly well, with the Shares Nasdaq Biotechnology Etf (NASDAQ: IBB ) outperforming the S&P 500 Index. This defensive sector also benefited from opportunity in the form of SARS-CoV-2, the virus that causes COVID-19. It, therefore, comes as a no surprise that two of the top five gainers among biotech stocks are vaccine developers. Here are the biotechs that advanced in excess of 1,000% thus far this year: Novavax, Inc. (NASDAQ: NVAX ) (Gain: +2799%) Much of Novavax's rally is attributable to its coronavirus vaccine program. The company identified its investigational vaccine, codenamed NVX-CoV2373, in early April. It is a stable, prefusion protein made using the company's proprietary nanoparticle technology, with Matrix-M adjuvant added to it. Ahead of the initiation of the coronavirus vaccine program, the shares received a lift from positive developments concerning its influenza vaccine candidate NanoFlu. After proceeding seamlessly with its vaccine program, Novavax Is currently facing a setback as it is experiencing a delay in the start of the U.S. leg of the late-stage study of NVX-CoV2373.
   iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) Downgraded to “Sell” at ValuEngine  2020/11/20 08:18:47 Transcript Daily
ValuEngine cut shares of iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) from a hold rating to a sell rating in a research report report published on Monday, ValuEngine reports. IBB opened at $138.09 on Monday. iShares Nasdaq Biotechnology ETF has a 52 week low of $92.15 and a 52 week high of $146.53. The company has a […]
   Biotech ETFs Poised for Gains after Moderna Vaccine News  2020/11/16 17:52:33 ETF Trends
Biotech ETFs are getting a boost along with stocks on Monday thanks to Moderna, which announced that its initial phase three trial data reveals a coronavirus vaccine that is over 94% effective. Shares of the Moderna surged over 12% in premarket trading, and are still up over 7.5%. Meanwhile, the iShares Nasdaq Biotechnology ETF (IBB) is […] The post Biotech ETFs Poised for Gains after Moderna Vaccine News appeared first on ETF Trends .
   Bluebird bio's stock plunges after submission delay of sickle cell disease treatment  2020/11/05 15:11:00 Yahoo Finance
Shares of Bluebird bio Inc. traded 15.1% into the red in morning trading Thursday, after the gene therapy company pushed back the U.S. submission for approval of its sickle cell disease treatment LentiGlobin to late-2022 from the second half of 2021. The stock was headed toward the lowest close since April 15. Regarding LentiGlobin, the company said late Wednesday the submission delay comes after the Food and Drug Administration requested the use of drug product manufactured from sickle cell disease patient cells in addition to healthy donors, to demonstrate drug product comparability. J.P. Morgan analyst Cory Kasimov kept his rating at overweight but slashed his price target to $76 from $140, saying LentiGlobin in sickle cell disease is "arguably the most important value driver" for Bluebird. "Although there is no change in our view on the clinical profile (it's hard to argue that the data to date has been anything short of impressive), these manufacturing related setbacks are getting old, painful and further call into question the company's ability to execute," Kasimov wrote in a note to clients.
   The Week Ahead In Biotech: Kala FDA Decision, Merck & Pfizer Earnings, Vaccine Updates And IPOs  2020/10/25 18:42:47 Benzinga
Biotech stocks posted weekly declines in the week ended Oct. 23, pressured by the broader market decline amid mixed earnings reports and the impasse on fiscal stimulus. After declining in the first three sessions of the week, the iShares Nasdaq Biotechnology Etf (NASDAQ: IBB ) rebounded in the next two, thereby recouping some of the losses. Biogen Inc's (NASDAQ: BIIB ) third-quarter report headlined the biopharma earnings news flow of the week. Although the initial reaction was positive due to the better-than-expected headline numbers, the stock came under selling pressure subsequently, as investors fretted over accelerating decline in Spinraza sales and the looming binary event for Alzheimer's treatment candidate aducanumab. On the coronavirus vaccine front, AstraZeneca plc (NASDAQ: AZN ) experienced another scare as a trial participant was reported as dead in Brazil. The U.K. biopharma, however, was vindicated as reports later said the said participant was administered placebo and not the investigational vaccine.
   5 Biotech Stocks That Generated 1,000%+ Returns In 2020  2020/12/26 15:30:02 Benzinga
The biopharma sector weathered the COVID-19 pandemic fairly well, with the Shares Nasdaq Biotechnology Etf (NASDAQ: IBB ) outperforming the S&P 500 Index. This defensive sector also benefited from opportunity in the form of SARS-CoV-2, the virus that causes COVID-19. It, therefore, comes as a no surprise that two of the top five gainers among biotech stocks are vaccine developers. Here are the biotechs that advanced in excess of 1,000% thus far this year: Novavax, Inc. (NASDAQ: NVAX ) (Gain: +2799%) Much of Novavax's rally is attributable to its coronavirus vaccine program. The company identified its investigational vaccine, codenamed NVX-CoV2373, in early April. It is a stable, prefusion protein made using the company's proprietary nanoparticle technology, with Matrix-M adjuvant added to it. Ahead of the initiation of the coronavirus vaccine program, the shares received a lift from positive developments concerning its influenza vaccine candidate NanoFlu. After proceeding seamlessly with its vaccine program, Novavax Is currently facing a setback as it is experiencing a delay in the start of the U.S. leg of the late-stage study of NVX-CoV2373.
   iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) Downgraded to “Sell” at ValuEngine  2020/11/20 08:18:47 Transcript Daily
ValuEngine cut shares of iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) from a hold rating to a sell rating in a research report report published on Monday, ValuEngine reports. IBB opened at $138.09 on Monday. iShares Nasdaq Biotechnology ETF has a 52 week low of $92.15 and a 52 week high of $146.53. The company has a […]
   Biotech ETFs Poised for Gains after Moderna Vaccine News  2020/11/16 17:52:33 ETF Trends
Biotech ETFs are getting a boost along with stocks on Monday thanks to Moderna, which announced that its initial phase three trial data reveals a coronavirus vaccine that is over 94% effective. Shares of the Moderna surged over 12% in premarket trading, and are still up over 7.5%. Meanwhile, the iShares Nasdaq Biotechnology ETF (IBB) is […] The post Biotech ETFs Poised for Gains after Moderna Vaccine News appeared first on ETF Trends .
   Bluebird bio's stock plunges after submission delay of sickle cell disease treatment  2020/11/05 15:11:00 Yahoo Finance
Shares of Bluebird bio Inc. traded 15.1% into the red in morning trading Thursday, after the gene therapy company pushed back the U.S. submission for approval of its sickle cell disease treatment LentiGlobin to late-2022 from the second half of 2021. The stock was headed toward the lowest close since April 15. Regarding LentiGlobin, the company said late Wednesday the submission delay comes after the Food and Drug Administration requested the use of drug product manufactured from sickle cell disease patient cells in addition to healthy donors, to demonstrate drug product comparability. J.P. Morgan analyst Cory Kasimov kept his rating at overweight but slashed his price target to $76 from $140, saying LentiGlobin in sickle cell disease is "arguably the most important value driver" for Bluebird. "Although there is no change in our view on the clinical profile (it's hard to argue that the data to date has been anything short of impressive), these manufacturing related setbacks are getting old, painful and further call into question the company's ability to execute," Kasimov wrote in a note to clients.
   The Week Ahead In Biotech: Kala FDA Decision, Merck & Pfizer Earnings, Vaccine Updates And IPOs  2020/10/25 18:42:47 Benzinga
Biotech stocks posted weekly declines in the week ended Oct. 23, pressured by the broader market decline amid mixed earnings reports and the impasse on fiscal stimulus. After declining in the first three sessions of the week, the iShares Nasdaq Biotechnology Etf (NASDAQ: IBB ) rebounded in the next two, thereby recouping some of the losses. Biogen Inc's (NASDAQ: BIIB ) third-quarter report headlined the biopharma earnings news flow of the week. Although the initial reaction was positive due to the better-than-expected headline numbers, the stock came under selling pressure subsequently, as investors fretted over accelerating decline in Spinraza sales and the looming binary event for Alzheimer's treatment candidate aducanumab. On the coronavirus vaccine front, AstraZeneca plc (NASDAQ: AZN ) experienced another scare as a trial participant was reported as dead in Brazil. The U.K. biopharma, however, was vindicated as reports later said the said participant was administered placebo and not the investigational vaccine.
   iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) Downgraded to “Sell” at ValuEngine  2020/11/20 08:18:47 Transcript Daily
ValuEngine cut shares of iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) from a hold rating to a sell rating in a research report report published on Monday, ValuEngine reports. IBB opened at $138.09 on Monday. iShares Nasdaq Biotechnology ETF has a 52 week low of $92.15 and a 52 week high of $146.53. The company has a […]
   Biotech ETFs Poised for Gains after Moderna Vaccine News  2020/11/16 17:52:33 ETF Trends
Biotech ETFs are getting a boost along with stocks on Monday thanks to Moderna, which announced that its initial phase three trial data reveals a coronavirus vaccine that is over 94% effective. Shares of the Moderna surged over 12% in premarket trading, and are still up over 7.5%. Meanwhile, the iShares Nasdaq Biotechnology ETF (IBB) is […] The post Biotech ETFs Poised for Gains after Moderna Vaccine News appeared first on ETF Trends .
   Bluebird bio's stock plunges after submission delay of sickle cell disease treatment  2020/11/05 15:11:00 Yahoo Finance
Shares of Bluebird bio Inc. traded 15.1% into the red in morning trading Thursday, after the gene therapy company pushed back the U.S. submission for approval of its sickle cell disease treatment LentiGlobin to late-2022 from the second half of 2021. The stock was headed toward the lowest close since April 15. Regarding LentiGlobin, the company said late Wednesday the submission delay comes after the Food and Drug Administration requested the use of drug product manufactured from sickle cell disease patient cells in addition to healthy donors, to demonstrate drug product comparability. J.P. Morgan analyst Cory Kasimov kept his rating at overweight but slashed his price target to $76 from $140, saying LentiGlobin in sickle cell disease is "arguably the most important value driver" for Bluebird. "Although there is no change in our view on the clinical profile (it's hard to argue that the data to date has been anything short of impressive), these manufacturing related setbacks are getting old, painful and further call into question the company's ability to execute," Kasimov wrote in a note to clients.
   The Week Ahead In Biotech: Kala FDA Decision, Merck & Pfizer Earnings, Vaccine Updates And IPOs  2020/10/25 18:42:47 Benzinga
Biotech stocks posted weekly declines in the week ended Oct. 23, pressured by the broader market decline amid mixed earnings reports and the impasse on fiscal stimulus. After declining in the first three sessions of the week, the iShares Nasdaq Biotechnology Etf (NASDAQ: IBB ) rebounded in the next two, thereby recouping some of the losses. Biogen Inc's (NASDAQ: BIIB ) third-quarter report headlined the biopharma earnings news flow of the week. Although the initial reaction was positive due to the better-than-expected headline numbers, the stock came under selling pressure subsequently, as investors fretted over accelerating decline in Spinraza sales and the looming binary event for Alzheimer's treatment candidate aducanumab. On the coronavirus vaccine front, AstraZeneca plc (NASDAQ: AZN ) experienced another scare as a trial participant was reported as dead in Brazil. The U.K. biopharma, however, was vindicated as reports later said the said participant was administered placebo and not the investigational vaccine.
   Aptinyx stock soars on premarket leading volume after positive trial results of PTSD treatment  2020/10/20 13:19:00 Yahoo Finance
Shares of Aptinyx Inc. shot up 61% on heavy volume in premarket trading Tuesday, putting them on track to open at a 20-month high, after the biopharmaceutical company reported positive results from a Phase 2 trial of its treatment for post-traumatic stress disorder (PTSD). Trading volume was 14.6 million shares, making the stock the most actively traded ahead of the open, and compared with the full-day average of about 269,000 shares. The company said its NYX-783 demonstrated "statistically significant and clinically meaningful efficacy results and a favorable adverse event and tolerability profile." As a result, the company expects to initiate a pivotal study in 2021. The stock, which is on track to open at the highest price seen during regular-session hours since February 2019, has gained 7.0% year to date through Monday, while the iShares Nasdaq Biotechnology ETF has rallied 14.0% and the S&P 500 has advanced 6.1%.

 twitter  (公式ツイッターやCEOツイッターなど)